miR-639 regulates transforming growth factor beta-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting FOXC1

Cancer Science

Volumn 105, Issue 10, 2014, Pages 1288-1298

  Lin, Zhaoyu ^a   Sun, Lijuan ^a   Chen, Weiliang ^a   Liu, Bodu ^a   Wang, Youyuan ^a   Fan, Song ^a   Li, Yilin ^b   Li, Jinsong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Xaverian Brothers High School   (United States)

Author keywords

Epithelial to mesenchymal transition; FOXC1; MiR 639; Tongue squamous cell carcinoma; Transforming growth factor beta

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; FOXC1 PROTEIN, HUMAN; MICRORNA; MIRN639 MICRORNA, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENETICS; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TONGUE TUMOR; TUMOR CELL LINE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; TONGUE NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84911120761     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12499     Document Type: Article

References (35)

1. Sano D, Myers JN. Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 2007; 26: 645-62.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
3. Yamada S, Fuchs BC, Fujii T et al. Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. Surgery 2013; 154: 946-54.
4. Moon HJ, Finney J, Xu L, Moore D, Welch DR, Mure M. MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro. J Biol Chem 2013; 288: 30000-8.
5. Liu R, Li J, Xie K et al. FGFR4 promotes stroma-induced epithelial-to- mesenchymal transition in colorectal cancer. Cancer Res 2013; 73: 5926-35.
6. Chen Y, Xiao Y, Ge W et al. miR-200b inhibits TGF-β1-induced epithelial-mesenchymal transition and promotes growth of intestinal epithelial cells. Cell Death Dis 2013; 4: e541.
7. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17: 548-58.
8. Chaudhury A, Hussey GS, Ray PS, Jin G, Fox PL, Howe PH. TGF-β-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat Cell Biol 2010; 12: 286-93.
9. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-8.
10. Shin SY, Rath O, Zebisch A, Choo SM, Kolch W, Cho KH. Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition. Cancer Res 2010; 70: 6715-24.
11. Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-90.
12. Huber MAAN, Baumann B, Grünert S et al. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004; 114: 569-81.
13. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 2009; 15: 195-206.
14. Sánchez-Tilló E, Lázaro A, Torrent R et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene 2010; 29: 3490-500.
15. Vuoriluoto K, Haugen H, Kiviluoto S et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 2010; 30: 1436-48.
16. Wellner U, Schubert J, Burk UC et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11: 1487-95.
17. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of Snail by NF-κB is required for inflammation-induced cell migration and invasion. Cancer Cell 2009; 15: 416-28.
18. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
19. Engel BM, Hutvagner G. Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene 2006; 25: 6163-9.
20. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006; 94: 776-80.
21. Sun L, Yao Y, Liu B et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 2012; 31: 432-45.
22. Du J, Li L, Ou Z et al. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells. Breast Cancer Res Treat 2012; 131: 65-73.
23. Xu ZY, Ding SM, Zhou L et al. FOXC1 contributes to microvascular invasion in primary hepatocellular carcinoma via regulating epithelial-mesenchymal transition. Int J Biol Sci 2012; 8: 1130-41.
24. Wei LX, Zhou RS, Xu HF, Wang JY, Yuan MH. High expression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients. Tumour Biol 2013; 34: 941-6.
25. Wang L, Gu F, Liu CY, Wang RJ, Li J, Xu JY. High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma. Tumour Biol 2013; 34: 853-8.
26. Xia L, Huang W, Tian D et al. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology 2013; 57: 610-24.
27. Zhou Y, Kato H, Asanoma K et al. Identification of FOXC1 as a TGF-beta1 responsive gene and its involvement in negative regulation of cell growth. Genomics 2002; 80: 465-72.
28. Gilad S, Meiri E, Yogev Y et al. Serum microRNAs are promising novel biomarkers. PLoS ONE 2008; 3: e3148.
29. Chua KN, Ma J, Thiery JP. Targeted therapies in control of EMT in carcinoma and fibrosis. Drug Discov Today 2008; 4: 261-7.
30. Shida T, Furuya M, Nikaido T et al. Sonic Hedgehog-Gli1 signaling pathway might become an effective therapeutic target in gastrointestinal neuroendocrine carcinomas. Cancer Biol Ther 2006; 5: 1530-8.
31. Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007; 67: 2187-96.
32. Krutzfeldt J, Rajewsky N, Braich R et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685-9.
33. Jeyaseelan K, Herath WB, Armugam A. MicroRNAs as therapeutic targets in human diseases. Expert Opin Ther Targets 2007; 11: 1119-29.
34. Spender LC, Inman GJ. TGF-β induces growth arrest in Burkitt lymphoma cells via transcriptional repression of E2F-1. J Biol Chem 2009; 284: 1435-42.
35. Petrocca F, Visone R, Onelli MR et al. E2F1-regulated microRNAs impair TGFβ-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 2008; 13: 272-86.